FBXO32 and neoplasm: As a tumor suppressor and a TGF-β/SMAD4 target gene, methylation of FBXO32 promoter correlates with poor ovarian cancer prognosis while reintroduction of FBXO32 can sensitize the cells to cisplatin treatment[70].